Michael J. Borowitz
#126,357
Most Influential Person Now
Michael J. Borowitz's AcademicInfluence.com Rankings
Michael J. Borowitzphilosophy Degrees
Philosophy
#5933
World Rank
#8870
Historical Rank
Logic
#3136
World Rank
#4253
Historical Rank
Download Badge
Philosophy
Why Is Michael J. Borowitz Influential?
(Suggest an Edit or Addition)Michael J. Borowitz's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. (2016) (6707)
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. (2009) (4395)
- Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. (2009) (1048)
- Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. (1988) (738)
- Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. (2009) (654)
- The genomic landscape of hypodiploid acute lymphoblastic leukemia (2013) (585)
- Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. (2008) (489)
- Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). (2007) (432)
- Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. (2010) (390)
- Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. (1996) (338)
- Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. (1993) (321)
- Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry (2010) (310)
- Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. (2015) (289)
- PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia (2019) (274)
- Antigens of human pancreatic adenocarcinoma cells defined by murine monoclonal antibodies. (1982) (267)
- Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse (2013) (257)
- Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. (1993) (257)
- Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. (2016) (256)
- International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. (2022) (249)
- Distribution of common acute lymphoblastic leukemia antigen in nonhematopoietic tissues (1981) (249)
- Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin. (2000) (248)
- Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia (2011) (244)
- Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study. (1992) (234)
- Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. (2017) (214)
- Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. (2008) (208)
- Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. (1992) (207)
- Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. (2012) (207)
- A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. (2012) (206)
- Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. (2008) (199)
- Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. (2009) (184)
- Measuring and comparing health care waiting times in OECD countries. (2014) (184)
- Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. (2012) (181)
- Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia (2016) (181)
- Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. (2010) (180)
- The 2008 Revision of the WHO Classification of Myeloid Neoplasms and Acute Leukemia : Rationale and Important Changes (2009) (177)
- Philadelphia chromosome positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study (1990) (176)
- Blastic natural killer cell leukemia/lymphoma: a clinicopathologic study. (1997) (173)
- The genetic basis and cell of origin of mixed phenotype acute leukaemia (2018) (171)
- Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. (2006) (166)
- A New Primary Effusion Lymphoma-Derived Cell Line Yields a Highly Infectious Kaposi's Sarcoma Herpesvirus-Containing Supernatant (2000) (162)
- IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. (2015) (161)
- Acute leukaemias of ambiguous lineage. . (2001) (159)
- Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). (2011) (159)
- Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. (2013) (159)
- Linkage between STAT Regulation and Epstein-Barr Virus Gene Expression in Tumors (2001) (157)
- Pathology Competencies for Medical Education and Educational Cases (2017) (151)
- Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. (2018) (150)
- Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. (2012) (147)
- Clinical and biologic features predict a poor prognosis in acute lymphoid leukemias in infants: a Pediatric Oncology Group Study. (1986) (143)
- Guidelines for interpreting EBER in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma. (2002) (142)
- Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. (2018) (136)
- Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404. (2016) (135)
- Waiting Time Policies in the Health Sector: What works? (2013) (134)
- Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. (2018) (129)
- Immature granulocyte measurement using the Sysmex XE-2100. Relationship to infection and sepsis. (2003) (129)
- Asynchronous Antigen Expression in B Lineage Acute Lymphoblastic Leukemia (1988) (128)
- New recurring cytogenetic abnormalities and association of blast cell karyotypes with prognosis in childhood T-cell acute lymphoblastic leukemia: a pediatric oncology group report of 343 cases. (2000) (127)
- Neutrophil‐Rich, Ki‐1-Positive Anaplastic Large‐Cell Malignant Lymphoma (1995) (124)
- U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: data analysis and interpretation. (1997) (123)
- Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies. (1989) (123)
- Predictability of the t(1;19)(q23;p13) from surface antigen phenotype: implications for screening cases of childhood acute lymphoblastic leukemia for molecular analysis: a Pediatric Oncology Group study. (1993) (122)
- Acute bilineal leukemia: a rare disease with poor outcome (2007) (121)
- Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. (2010) (121)
- Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. (2010) (120)
- Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group. (2013) (116)
- Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. (2021) (114)
- Clinicopathologic and cytogenic features of CD34 (My 10)-positive acute nonlymphocytic leukemia. (1989) (114)
- Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting. (2001) (113)
- The hospital of the future in China: China's reform of public hospitals and trends from industrialized countries. (2014) (110)
- Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. (2012) (106)
- TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. (2018) (106)
- Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. (2000) (105)
- The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. (2014) (103)
- Paying For Performance In Healthcare: Implications For Health System Performance And Accountability (2014) (102)
- Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3) translocation. (1999) (101)
- 2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: Medical indications (2007) (101)
- Childhood social environment and Hodgkin's lymphoma: new findings from a population-based case-control study. (2004) (100)
- Prognostic significance of CD34 expression in childhood B-precursor acute lymphocytic leukemia: a Pediatric Oncology Group study. (1990) (99)
- Immunoglobulin and T cell receptor gene rearrangements in human lymphoma and leukemia. (1987) (99)
- CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment (2017) (98)
- Near-triploid and near-tetraploid acute lymphoblastic leukemia of childhood. (1990) (98)
- Flow cytometry in the diagnosis of acute leukemia. (2001) (97)
- International comparisons of waiting times in health care--limitations and prospects. (2013) (97)
- The accuracy of combined cytopathologic and flow cytometric analysis of fine-needle aspirates of lymph nodes. (2000) (94)
- Clinical presentation, karyotypic characterization, and treatment outcome of childhood acute lymphoblastic leukemia with a near-haploid or hypodiploid less than 45 line (1990) (94)
- Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia. (2010) (91)
- Prognostic importance of the pre-B-cell immunophenotype and other presenting features in B-lineage childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. (1989) (90)
- Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: Implications for residual disease detection: A report from the children's oncology group (2005) (89)
- Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group. (2010) (84)
- Immature Granulocyte Measurement Using the Sysmex XE-2100 (2003) (83)
- Lack of surface immunoglobulin light chain expression by flow cytometric immunophenotyping can help diagnose peripheral B-cell lymphoma. (2002) (83)
- Defective glycosylphosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglobinuria granulocytes. (1992) (82)
- Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology. (2017) (80)
- Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. (2014) (80)
- Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group. (2018) (79)
- Re‐induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2 (2015) (79)
- Characterization and distribution of a 24,000-molecular weight antigen defined by a monoclonal antibody (DU-ALL-1) elicited to common acute lymphoblastic leukemia (cALL) cells. (1982) (78)
- Transmission of a T-cell lymphoma by allogeneic bone marrow transplantation. (2001) (77)
- Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. (2012) (77)
- Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. (1998) (76)
- Monoclonal antibodies against human pancreatic adenocarcinoma: distribution of DU-PAN-2 antigen on glandular epithelia and adenocarcinomas. (1984) (76)
- Immunophenotypes and karyotypes of leukemic cells in children with Down syndrome and acute lymphoblastic leukemia. (1993) (76)
- Characterization of the human tumor and normal tissue reactivity of the KS1/4 monoclonal antibody. (1988) (76)
- NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, (2010) (76)
- Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. (1990) (75)
- Clinical utility of flow cytometry in the chronic lymphoid leukemias. (1998) (75)
- Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493). (1997) (74)
- Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331. (2019) (73)
- Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model. (2012) (71)
- A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. (1988) (71)
- Aspirin and the risk of Hodgkin's lymphoma in a population-based case-control study. (2004) (71)
- A clinical evaluation of high fluorescent platelet fraction percentage in thrombocytopenia. (2006) (69)
- Favorable prognosis associated with hyperdiploidy in children with acute lymphocytic leukemia correlates with extra chromosome 6. A pediatric oncology group study (1990) (69)
- Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study (1990) (69)
- Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: Results of Children's Oncology Group trial P9906 (2011) (66)
- FLT3 mutations in myeloid sarcoma (2004) (66)
- More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. (2019) (65)
- Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes (2006) (64)
- Glucocorticoid receptors in immunological subtypes of childhood acute lymphocytic leukemia cells: a Pediatric Oncology Group Study. (1985) (64)
- An anti‐CD5 immunotoxin for chronic lymphocytic leukemia: Enhancement of cytotoxicity with human serum albumin‐monensin (1989) (64)
- Attempt at deriving a formula for setting general practitioner fundholding budgets (1994) (63)
- Phase II treatment of medulloblastoma and pineoblastoma with melphalan: clinical therapy based on experimental models of human medulloblastoma. (1989) (63)
- Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. (2009) (62)
- Clinical presentation, karyotypic characterization, and treatment outcome of childhood acute lymphoblastic leukemia with a near-haploid or hypodiploid less than 45 line. (1990) (59)
- Simplified flow cytometric assessment in mycosis fungoides and Sézary syndrome. (2011) (57)
- Trisomy 21 in childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study (8602). (1993) (57)
- Heterogeneity of risk factors and antibody profiles in epstein-barr virus genome-positive and -negative hodgkin lymphoma. (2004) (57)
- Abnormalities of circulating T-cell subpopulations in patients with cutaneous T-cell lymphoma: cutaneous lymphocyte-associated antigen expression on T cells correlates with extent of disease. (1993) (57)
- THE UPDATED WHO CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES The 2016 revision to the World Health Organization classi fi cation of myeloid neoplasms and acute leukemia (2016) (56)
- Philadelphia chromosome positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study. (1990) (54)
- Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage (2015) (54)
- Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested? (2015) (54)
- Detection of paroxysmal nocturnal hemoglobinuria clones to exclude inherited bone marrow failure syndromes (2014) (54)
- Asynchronous antigen expression in B lineage acute lymphoblastic leukemia. (1988) (54)
- Acute lymphoid leukemia in adolescents: clinical and biologic features predict a poor prognosis--a Pediatric Oncology Group Study. (1988) (50)
- Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. (2017) (50)
- Hepatosplenic T-cell lymphoma: An unusual case of a γδ T-cell lymphoma with a blast-like terminal transformation (1994) (50)
- Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia. (1996) (49)
- Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. (2005) (47)
- Bortezomib reinduction chemotherapy in high‐risk ALL in first relapse: a report from the Children's Oncology Group (2019) (46)
- Atypical prediagnosis Epstein-Barr virus serology restricted to EBV-positive Hodgkin lymphoma. (2012) (46)
- Diagnostic problems in the cytologic evaluation of cerebrospinal fluid for lymphoma and leukemia. (1981) (45)
- Immunologic markers in childhood acute lymphoblastic leukemia. (1990) (45)
- Human t(1;19)(q23;p13) pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency. (1993) (45)
- Lymphoblastic lymphoma with the phenotype of common acute lymphoblastic leukemia. (1983) (44)
- Primary Epstein-Barr virus-associated Hodgkin disease of the ileum complicating Crohn disease. (2001) (44)
- Immunologic and clinicopathologic features of common acute lymphoblastic leukemia antigen‐positive childhood T‐cell leukemia A pediatric oncology group study (1987) (44)
- changes of myeloid neoplasms and acute leukemia: rationale and important The 2008 revision of the World Health Organization (WHO) classification (2013) (43)
- Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study AALL0232. (2011) (42)
- Overexpression of CD49f in precursor B‐cell acute lymphoblastic leukemia: Potential usefulness in minimal residual disease detection (2009) (42)
- Reinduction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Results From Children's Oncology Group (COG) Study ADVL04P2 (2011) (41)
- Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group. (2008) (41)
- Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL (2021) (40)
- Mental health and the development agenda in Sub-Saharan Africa. (2010) (40)
- Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics. (2019) (40)
- The transglutaminase in vascular cells and tissues could provide an alternate pathway for fibrin stabilization. (1987) (40)
- Primary Cutaneous T-Cell–Rich B-Cell Lymphoma: Clinically Distinct from Its Nodal Counterpart? (2001) (39)
- Changing the measure of quality in the NHS: from purchasing activity to purchasing protocols. (1993) (39)
- Flow cytometric reticulocyte analysis. Multiinstitutional interlaboratory correlation study. (1994) (39)
- Extranodal head and neck lymphoma. Prognosis and patterns of recurrence. (1990) (38)
- Clinical and biological heterogeneity of childhood B cell acute lymphocytic leukemia: implications for clinical trials. (1990) (38)
- Improved Early Event Free Survival (EFS) in Children with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) with Intensive Imatinib in Combination with High Dose Chemotherapy: Children’s Oncology Group (COG) Study AALL0031. (2007) (38)
- tdic(9;12): A nonrandom chromosome abnormality in childhood B-cell precursor acute lymphoblastic leukemia: A pediatric oncology group study (1987) (38)
- Immunocytochemical detection of lymphocyte surface antigens in fixed tissue sections. (1982) (37)
- Cooperative effects of gamma interferon and 1-alpha,25-dihydroxyvitamin D3 in inducing differentiation of human promyelocytic leukemia (HL-60) cells. (1986) (37)
- Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children’s Oncology Group (COG) (2017) (36)
- Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group. (2019) (36)
- The non-random dic(9;12) translocation in acute lymphoblastic leukemia is associated with B-progenitor phenotype and an excellent prognosis. (1992) (36)
- Acute lymphoblastic leukemia of Burkitt's type (L3 ALL) with 8;22 and 14;18 translocations and absent surface immunoglobulins. (1986) (36)
- Consolidation therapy with antimetabolite-based therapy in standard-risk acute lymphocytic leukemia of childhood: a Pediatric Oncology Group Study. (1998) (35)
- The unfinished journey from Semashko to Bismarck: health reform in Central Asia from 1991 to 2006 (2006) (35)
- Clinical and pathologic features of secondary acute promyelocytic leukemia. (2012) (35)
- Patients with Early T-Cell Precursor (ETP) Acute Lymphoblastic Leukemia (ALL) Have High Levels of Minimal Residual Disease (MRD) at the End of induction—A Children's Oncology Group (COG) Study. (2009) (35)
- Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high‐risk stratum of patients with newly diagnosed high‐risk B‐lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131 (2018) (35)
- Isochromosomes in childhood acute lymphoblastic leukemia: a collaborative study of 83 cases. (1992) (35)
- ICCS/ESCCA Consensus Guidelines to detect GPI‐deficient cells in Paroxysmal Nocturnal Hemoglobinuria (PNH) and related Disorders Part 1 – Clinical Utility (2018) (35)
- A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621 (2019) (34)
- High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement. (2005) (34)
- The gender gap in primary health care resource utilization in Central Asia. (2002) (34)
- Gastrointestinal involvement and multiple lymphomatous polyposis in mantle-zone lymphoma. (1986) (34)
- Outcome modeling with CRLF 2 , IKZF 1 , JAK , and minimal residual disease in pediatric acute lymphoblastic leukemia : a Children ’ s Oncology Group Study (2012) (33)
- NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic (2010) (33)
- Impact of the Medicare fee schedule on payments to physicians. (1990) (32)
- Precursor T lymphoblastic leukaemia/lymphoblastic lymphoma. (Precursor T-cell acute lymphoblastic leukaemia). . (2001) (32)
- Peripheral T-cell lymphomas of follicular helper T-cell type frequently display an aberrant CD3−/dimCD4+ population by flow cytometry: an important clue to the diagnosis of a Hodgkin lymphoma mimic (2016) (32)
- High glucocorticoid receptor content of leukemic blasts is a favorable prognostic factor in childhood acute lymphoblastic leukemia (1993) (31)
- Atypical clonal T-cell proliferation in infectious mononucleosis (1996) (31)
- Inherited genetic susceptibility of acute lymphoblastic leukemia in Down syndrome. (2019) (31)
- U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry. Bethesda, Maryland, November 16-17, 1995. (1997) (31)
- The genomic landscape of pediatric acute lymphoblastic leukemia (2022) (31)
- Heterogeneity of antigen expression in benign and malignant breast and ovarian epithelial cells (1989) (30)
- Flow cytometric findings in hemophagocytic lymphohistiocytosis. (2012) (30)
- Monoclonal antibody definition of T cell acute leukemia: a Pediatric Oncology Group study. (1985) (30)
- Immunohistochemical analysis of the distribution of lymphocyte subpopulations in Hodgkin's disease. (1982) (30)
- Human B-cell lymphoma in severe combined immunodeficient mice after active infection with Epstein-Barr virus. (1992) (30)
- Myeloid-antigen expression in childhood acute lymphoblastic leukemia. (1991) (29)
- Consistency of Isochromosome 7q and Trisomy 8 in Hepatosplenic γδ T-cell Lymphoma: Detection by Fluorescence In Situ Hybridization of a Splenic Touch-Preparation from a Pediatric Patient (1999) (29)
- Familial Hodgkin's disease a clinical and laboratory investigation (1987) (29)
- A QA Program for MRD Testing Demonstrates That Systematic Education Can Reduce Discordance Among Experienced Interpreters (2018) (29)
- Triacylglycerol turnover in Tetrahymena pyriformis. Relation to phospholipid synthesis. (1976) (29)
- Laboratory correlates and prognostic significance of granular acute lymphoblastic leukemia in children. A Pediatric Oncology Group study. (1991) (28)
- Comparison of histologic and immunologic heterogeneity of non-Hodgkin's lymphomas. (1981) (28)
- Assessing Fiscal Space for Health in the SDG Era: A Different Story (2018) (28)
- Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children's Oncology Group. (2019) (28)
- Isochromosomes in Childhood Acute Lymphoblastic Leukemia: A Collaborative Study of 83 Cases (1992) (28)
- FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631 (2021) (27)
- Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932 (2021) (27)
- HHV-8-positive and EBV-positive intravascular lymphoma: an unusual presentation of extracavitary primary effusion lymphoma. (2014) (27)
- Diagnostic applications of monoclonal antibodies to human cancer. (1984) (26)
- The usefulness of CD71 expression by flow cytometry for differentiating indolent from aggressive CD10+ B-cell lymphomas. (2006) (25)
- Transitional pre-B-cell acute lymphoblastic leukemia of childhood is associated with favorable prognostic clinical features and an excellent outcome: a Pediatric Oncology Group study. (1993) (25)
- High glucocorticoid receptor content of leukemic blasts is a favorable prognostic factor in childhood acute lymphoblastic leukemia. (1993) (25)
- Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma. (2001) (25)
- Quantitative analysis of the change of metabolite fluxes along the pentose phosphate and glycolytic pathways in Tetrahymena in response to carbohydrates. (1977) (24)
- A phase 1 trial of temsirolimus and intensive re‐induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114) (2017) (24)
- Absolute lymphocyte counts refine minimal residual disease‐based risk stratification in childhood acute lymphoblastic leukemia (2012) (24)
- Preconditioning with fetal cord blood facilitates engraftment of primary childhood T-cell acute lymphoblastic leukemia in immunodeficient mice. (2001) (23)
- Clinicopathologic aspects of E rosette negative T cell acute lymphocytic leukemia: a Pediatric Oncology Group study. (1986) (23)
- Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131. (2020) (23)
- Understanding the Medicare Fee Schedule and its Impact on Physicians Under the Final Rule (1992) (23)
- The pharmaceutical industry and health reform: lessons from Europe. (1994) (23)
- Identification of newly diagnosed children with acute lymphocytic leukemia at high risk for relapse (1999) (23)
- Standardizing Leucocyte PNH clone detection: An international study. (2014) (23)
- CA180-372: An International Collaborative Phase 2 Trial of Dasatinib and Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) (2017) (22)
- Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): Review from an international consensus conference (2010) (22)
- Hepatosplenic T-cell lymphoma: an unusual case of a gamma delta T-cell lymphoma with a blast-like terminal transformation. (1994) (22)
- Prevalence of myeloperoxidase gene expression in infant acute lymphocytic leukemia. (1998) (22)
- Aberrant STAT 5 and PI 3 K / mTOR pathway signaling occurs in human CRLF 2-rearranged B-precursor acute lymphoblastic leukemia (2012) (21)
- Multiple assay characterization of murine monoclonal antimelanoma antibodies. (1982) (20)
- Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG (2018) (20)
- Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children’s Oncology Group phase III study AALL0433 (2020) (20)
- Immunophenotyping of acute leukemia by flow cytometry (1993) (20)
- Marrow B-cell precursors are increased in lymphomas or systemic diseases associated with B-cell dysfunction. (1993) (19)
- Changes in red blood cell methotrexate pharmacology and their impact on outcome when cytarabine is infused with methotrexate in the treatment of acute lymphocytic leukemia in children: a pediatric oncology group study. (1996) (19)
- Inter- and Intra-Observer Reliability of Epstein – Barr Virus Detection in Hodgkin Lymphoma using Histochemical Procedures (2004) (19)
- Software-automated counting of Ki-67 proliferation index correlates with pathologic grade and disease progression of follicular lymphomas. (2013) (19)
- Clonal cytogenetic abnormalities and BCL2 rearrangementin interdigitating dendritic cell sarcoma (2006) (19)
- Factors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation. (2014) (18)
- Bortezomib reinduction therapy to improve response rates in pediatric ALL in first relapse: A Children’s Oncology Group (COG) study (AALL07P1). (2013) (17)
- Detection of an oncofetal antigen (DU‐PAN‐2) in sera of patients with non‐malignant hepatobiliary diseases and hepatomas (1988) (17)
- Outcome of Children with Standard‐Risk T‐Lineage Acute Lymphoblastic Leukemia—Comparison among Different Treatment Strategies (2016) (17)
- Dexamethasone (DEX) versus prednisone (PRED) during induction for children with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study AALL0232. (2011) (17)
- Absence of ABH antigens on neutrophils (1985) (17)
- Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children’s Oncology Group Study AALL0232 (2021) (17)
- Differential diagnosis of undifferentiated malignant tumors with monoclonal antibody T29/33. (1984) (17)
- Controlling health care: from economic incentives to micro-clinical regulation. (1993) (17)
- Correlation of monoclonal antibody phenotyping and cellular DNA content in non‐Hodgkin's lymphoma. The southeastern cancer study group experience (1987) (16)
- Primary effusion lymphoma presenting as a cutaneous intravascular lymphoma (2014) (16)
- Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. (2008) (16)
- Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children’s Oncology Group (COG) Study AALL0331 (2014) (16)
- Genomic Profiling for Clinical Decision Making in Myeloid Neoplasms and Acute Leukemia. (2022) (16)
- T‐cell receptor antibodies in the immunohistochemical studies of normal and malignant lymphoid cells (1988) (16)
- Different patterns of relapse associated with three intensive treatment regimens for pediatric E-rosette positive T-cell leukemia: a Pediatric Oncology Group study. (1992) (16)
- A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia. (1998) (16)
- Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia (2013) (15)
- Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621 (2022) (15)
- Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells (2022) (15)
- Remission, treatment failure, and relapse in pediatric ALL: An international consensus of the Ponte-di-Legno Consortium. (2021) (15)
- Monoclonal immunoglobulin-secreting lymphoma in a patient with severe combined immunodeficiency disease. (1982) (14)
- Composite lymphoma: a unique case with two immunologically distinct B-cell neoplasms. (1984) (14)
- The Flow Cytometric Evaluation of Hematopoietic Neoplasia (2011) (14)
- T-cell lymphoma mimicking granulocytic sarcoma. (1985) (14)
- Use of clinical and laboratory features to define prognostic subgroups in B-precursor acute lymphoblastic leukemia: experience of the Pediatric Oncology Group. (1993) (14)
- DNA ploidy of malignant melanoma determined by image cytometry of fresh frozen and paraffin‐embedded tissue (1991) (13)
- Membrane Antigens of Human Myeloid Cells Defined by Monoclonal Antibodies (1984) (13)
- CD79a(+) T-cell lymphoblastic lymphoma with coexisting Langerhans cell histiocytosis. (2001) (13)
- Leukemias and lymphomas of thymic differentiation. (1988) (13)
- R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma (2019) (13)
- Detection of terminal deoxynucleotidyl transferase by flow cytometry: a three color method. (1994) (13)
- t(2;14)(p13;q32): a recurring abnormality in lymphocytic leukemia. A Pediatric Oncology Group study. (1992) (12)
- A BCR-ABL1-Like Gene Expression Profile Confers a Poor Prognosis In Patients with High-Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report From Children's Oncology Group (COG) AALL0232 (2011) (12)
- Absence of Biallelic TCR (cid:1) Deletion Predicts Early Treatment Failure in Pediatric T-Cell Acute Lymphoblastic Leukemia (2010) (12)
- Hematological Manifestations of Nephropathic Cystinosis (2008) (12)
- Cytogenetic and early-response characteristics of adolescents and young adults with acute lymphoblastic leukemia (ALL): A Children's Oncology Group (COG) study. (2010) (11)
- Tissue distribution and cellular location of the antigens recognized by human monoclonal antibodies 16.88 and 28A32. (1988) (11)
- report from The Children's Oncology Group TARGET Project Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a (2012) (11)
- Association of GATA3 polymorphisms with minimal residual disease and relapse risk in childhood acute lymphoblastic leukemia. (2020) (11)
- A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs): A Report from Children's Oncology Group Study AALL1331 (2021) (11)
- Delayed Intensification (DI) Enhances Event-Free Survival (EFS) of Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Who Received Intensification Therapy with Six Courses of Intravenous Methotrexate (MTX): POG 9904/9905: A Childrens Oncology Group Study (COG). (2007) (11)
- Aberrant expression of monoclonal antibody-defined colonic mucosal antigens in inflammatory bowel disease. (1988) (11)
- The Evolution of Earned, Transparent, and Quantifiable Faculty Salary Compensation (2018) (10)
- Tumor-Infiltrating Macrophages in Post-Transplant, Relapsed Classical Hodgkin Lymphoma Are Donor-Derived (2016) (10)
- Flow cytometry testing in PNH. How much is enough? (2000) (10)
- Outcomes of dasatinib plus intensive chemotherapy or stem cell transplant (SCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) on Children’s Oncology Group AALL0622. (2015) (10)
- Standardizing leucocyte PNH clone detection: An international study (2014) (10)
- Masked Hypodiploidy: Hypodiploid Acute Lymphoblastic Leukemia (ALL) in Children Mimicking Hyperdiploid ALL: A Report From the Children's Oncology Group (COG) AALL03B1 Study. (2009) (10)
- Extramedullary recurrence of acute lymphoblastic leukemia 15 years after initial diagnosis. (1984) (10)
- SVSI: Fast and Powerful Set‐Valued System Identification Approach to Identifying Rare Variants in Sequencing Studies for Ordered Categorical Traits (2015) (9)
- Biology-Driven Classification of Childhood Acute Lymphoblastic Leukemia: A Combined Analysis of Prognostic Markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG). (2004) (9)
- Myeloperoxidase gene expression in infant leukemia: a Pediatric Oncology Group Study. (1998) (9)
- International approaches to measuring the quality of mental health care (2013) (9)
- A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children’s Oncology Group Study AALL08P1 (2016) (9)
- Continuous Dose Dasatinib Is Safe and Feasible in Combination with Intensive Chemotherapy in Pediatric Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Children's Oncology Group (COG) Trial AALL0622 (2012) (9)
- Feasibility of treating post-transplantation minimal residual disease in children with acute leukemia. (2014) (9)
- The Medicare Fee Schedule unveiled: an account of physician payment reform. (1992) (8)
- Cytotoxic T-cell Allotaxis in Human Kidney Rejection (1982) (8)
- Phylogenetic distribution of a 24,000 dalton human leukemia-associated antigen on platelets and kidney cells. (1984) (8)
- Prognostic Significance of Minimal Residual Disease (MRD) in Childhood B-Precursor ALL and Its Relation to Other Risk Factors. A Children’s Oncology Group (COG) Study. (2006) (8)
- International Consensus Classification of acute lymphoblastic leukemia/lymphoma (2022) (8)
- Mixed Phenotype Acute Leukemia. (2013) (8)
- Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcoma (2013) (8)
- Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia (2018) (8)
- Mixed phenotype acute leukemia (2013) (8)
- HIV and AIDS financing in South Africa : sustainability and fiscal space (2016) (8)
- Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331 (2021) (8)
- Ret-Y a measure of reticulocyte size: a sensitive indicator of iron deficiency anemia. (2004) (7)
- Flow cytometry of lesional skin enhances the evaluation of cutaneous B‐cell lymphomas (2012) (7)
- Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine) Does Not Improve Disease-Free Survival Versus Intrathecal Methotrexate Alone in Children with High Risk B-Lymphoblastic Leukemia: Results of Children's Oncology Group Study AALL1131 (2018) (7)
- Outcomes of Children with First Marrow Relapse: Results from Children’s Oncology Group (COG) Study AALL01P2. (2006) (7)
- A novel variant three-way translocation of inversion 16 in a case of AML-M4eo following low dose methotrexate therapy. (2001) (7)
- Genotypic divergence precedes clinical dissemination in a case of synchronous bilateral B-cell malignant lymphoma of the testes. (1993) (7)
- KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy (2021) (7)
- Excellent Outcomes with Reduced Frequency of Vincristine and Dexamethasone Pulses in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): A Report from Children's Oncology Group (COG) Study AALL0932 (2019) (7)
- Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Children’s Oncology Group (2019) (7)
- Evaluation of CD22 modulation as a mechanism of resistance to inotuzumab ozogamicin (InO): Results from central CD22 testing on the Children’s Oncology Group (COG) phase II trial of INO in children and young adults with CD22+ B-acute lymphoblastic leukemia (B-ALL). (2020) (7)
- Practical application of monoclonal antibodies to the diagnosis and classification of acute leukaemias. (1987) (7)
- A review of waiting times policies in 13 OECD countries (2013) (6)
- Prognostic Significance of Minimal Residual Disease (MRD) in Children with High Risk Acute Lymphoblastic Leukemia(ALL) A Children’s Oncology Group Study. (2005) (6)
- The use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous bone marrow transplantation. (1990) (6)
- Striking Predictive Power For Relapse and Decreased Survival Associated With Detectable Minimal Residual Disease by IGH VDJ Deep Sequencing Of Bone Marrow Pre- and Post-Allogeneic Transplant In Children With B-Lineage ALL: A Subanalysis Of The COG ASCT0431/PBMTC ONC051 Study (2013) (6)
- Expression of a melanoma-tumor-associated antigen as demonstrated by a monoclonal antibody (D6.1) in cytopathologic preparations of human tumor cells from effusions and needle aspirates. (1985) (6)
- Targeted pathologic evaluation of bone marrow donors identifies previously undiagnosed marrow abnormalities. (2013) (6)
- Outcomes after Intermediate-Risk Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) and the Role of Allogeneic Stem Cell Transplantation (SCT): A Report from Children's Oncology Group (COG) AALL0433 (2014) (6)
- Improved Post-Induction Chemotherapy Does Not Abrogate Prognostic Significance of Minimal Residual Disease (MRD) for Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (ALL). A Report From Children's Oncology Group (COG) Study AALL0232 (2011) (6)
- Outcomes of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Based on Blast Genotype at Diagnosis: A Report from the Children's Oncology Group (2016) (6)
- Special Reports U.S.-Canadian Consensus Recommendations on the Immunophenotypic Analysis of Hematologic Neoplasia by Flow Cytometry (1997) (6)
- Nelarabine Can Be Safely Incorporated into an Intensive, Multiagent Chemotherapy Regimen for the Treatment of T-Cell Acute Lymphocytic Leukemia (ALL) in Children: A Report of the Children’s Oncology Group (COG) AALL00P2 Protocol for T-Cell Leukemia. (2006) (6)
- Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study AALL0232. (2011) (6)
- Intensification of Oral Methotrexate Is Not Superior to Standard Methotrexate Dosing during Maintenance in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): A Report from Children's Oncology Group (COG) Study AALL0932 (2017) (6)
- A Leukemic Presentation of Alveolar Rhabdomyosarcoma in a 52-Year-Old Woman Without an Identifiable Primary Tumor (2015) (6)
- Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children’s Oncology Group Studies P9904 and P9905 (2019) (6)
- The Relationship of Acute Gvhd and Pre- and Post-Transplant Flow-MRD to the Incidence and Timing of Relapse in Children Undergoing Allogeneic Transplantation for High Risk ALL: Defining a Target Population and Window for Immunological Intervention to Prevent Relapse (2012) (5)
- Sex‐based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children’s Oncology Group report (2022) (5)
- Assessment of end induction minimal residual disease (MRD) in childhood B precursor acute lymphoblastic leukemia (ALL) to eliminate the need for day 14 marrow examination: A Children’s Oncology Group study. (2013) (5)
- The Interaction of Calcium with Monolayers of Stearic and Oleic Acid (1970) (5)
- Thymic Stromal Lymphopoietin Stimulation of Pediatric Acute Lymphoblastic Leukemias with CRLF2 Alterations Induces JAK/STAT and PI3K Phosphosignaling (2010) (5)
- Persistent Multiyear Control of Relapsed T‐Cell Acute Lymphoblastic Leukemia With Successive Donor Lymphocyte Infusions: A Case Report (2016) (5)
- Studies on a Epithelial/Epithelial Malignancy Associated Antigen Associated with Human Adenocarcinomas (1987) (5)
- The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia (2019) (5)
- The Johns Hopkins Department of Pathology Novel Organizational Model: A 25-Year-Old Ongoing Experiment (2018) (5)
- A clinician's guide to the updated REAL/WHO classification of non-Hodgkin's lymphoma: part II (aggressive lymphomas) (2000) (5)
- Outstanding outcomes in infants with KMT2Agermline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children’s Oncology Group AALL0631 trial (2022) (5)
- An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys (2004) (5)
- Changes in the Delivery of Standard Chemotherapeutic Agents during Induction Affect Early Measures of Minimal Residual Disease (MRD): POG 9900 for Patients with B-Precursor Low and Standard Risk ALL. (2006) (5)
- Improving the quality of health systems (2004) (5)
- iAMP21 Is Associated with Inferior Outcomes in Children with Acute Lymphoblastic Leukemia (ALL) on Contemporary Children's Oncology Group (COG) Studies (2011) (4)
- Nelarabine May Be Safely Incorporated Into a Phase III Study for Newly Diagnosed T-Lineage Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group (2010) (4)
- tdic(9;12): a nonrandom chromosome abnormality in childhood B-cell precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. (1987) (4)
- No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy (2019) (4)
- Burkitt's and other non-Hodgkin's lymphomas in adults exposed to a visitor from Africa. (1985) (4)
- Residual Disease Monitoring By High Throughput Sequencing Provides Risk Stratification in Childhood B-ALL and Identifies a Novel Subset of Patients Having Poor Outcome (2016) (4)
- Chemoimmunotherapy reinduction with epratuzumab in children with ALL with marrow relapse: A Children's Oncology Group (COG) pilot study (ADVL04P2) (2007) (4)
- Outcomes of Patients with CRLF2-Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children's Oncology Group (2020) (4)
- Genetic and Response-Based Risk Classification Identifies a Subgroup of NCI High Risk Childhood B-Lymphoblastic Leukemia (HR B-ALL) with Outstanding Outcomes: A Report from the Children's Oncology Group (COG) (2015) (4)
- Nelarabine in combination with intensive modified BFM AALL00P2: A pilot study for the treatment of high risk T-ALL a report from the Children’s Oncology Group (2008) (3)
- The impact of initial cerebrospinal fluid (CSF) findings on outcome among patients with NCI standard (SR) and high-risk (HR) B-lymphoblastic leukemia (ALL): A report from the Children’s Oncology Group (COG) Studies AALL0331 and AALL0232. (2014) (3)
- Monitoring of Minimal Residual Disease before and after Allogeneic Stem Cell Transplantation Childhood ALL - a Retrospective Assessment on Behalf of the PDWP of the EBMT, the COG, PBMTC, the I-BFM and the Westhafen-Intercontinental-Group (2016) (3)
- Effective Targeting of Leukemic Cells in Children with B-Precursor Acute Lymphoblastic Leukemia Treated with Anti-CD22 (Epratuzumab). A Children’s Oncology Group (COG) Study. (2006) (3)
- Acid phosphatase positivity in childhood acute lymphocytic leukemia. (1986) (3)
- Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report (2020) (3)
- Precursor B- and T-Cell Neoplasms (2011) (3)
- Outcomes with reduced intensity therapy in a low-risk subset of children with National Cancer Institute (NCI) standard-risk (SR) B-lymphoblastic leukemia (B-ALL): A report from Children’s Oncology Group (COG) AALL0932. (2020) (3)
- Abstracts From the 48th Congress of the International Society of Paediatric Oncology (SIOP) Dublin, Ireland October 19-22, 2016. (2016) (3)
- Waiting times for health care: A conceptual framework (2013) (3)
- Monoclonal antibody L/1C2 reactive with a human carcinoma associated antigen. (1989) (3)
- D6.1, a murine antimelanoma monoclonal antibody from congenitally athymic nude mice immunized with purified melanoma tumor-associated antigen. (1984) (3)
- Application Note Productivity and Efficiency of 6-Color BD Multitest and BD Trucount Technologies for Enumeration of Lymphocyte Subsets (2007) (3)
- High-Throughput Screening by Flow Cytometry Identifies Reduced Expression of CD48 As a Universal Characteristic of T-ALL and a Suitable Target for Minimal Residual Disease (MRD) Detection (2011) (3)
- Leucine catabolism and CO2 fixation into fatty acids by Tetrahymena: evidence for two pools of CO2. (1977) (3)
- The significance of minimal residual disease (MRD) in relapsed childhood B-lymphoblastic leukemia (B-ALL): A report from Children’s Oncology Group (COG) protocol AALL0433. (2014) (3)
- Outcomes of Autologous and Allogeneic BMT for Mantle Cell Lymphoma. (2004) (3)
- The Clinical Relevance of Acute Myeloid Leukemia Stem Cells (2011) (3)
- Measuring waiting times across OECD countries (2013) (3)
- Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials. (2023) (3)
- FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631, a Children's Oncology Group Study (2019) (3)
- Technical assistance in developing a health insurance reform demonstration in Issyk-Kul oblast Kyrgyzstan: progress problems and prospects. (1994) (3)
- Measurable Residual Disease Detection in B‐Acute Lymphoblastic Leukemia: The Children's Oncology Group (COG) Method (2022) (3)
- Abstract 4729: Frequency of actionable gene fusions in patients with Philadelphia chromosome-like (Ph-like) B-acute lymphoblastic leukemia (ALL): A retrospective study from the Children's Oncology Group (COG) (2015) (2)
- Outcomes in children with Down syndrome (DS) and B-lymphoblastic leukemia (B-ALL): A Children’s Oncology Group (COG) report. (2020) (2)
- Minimal Residual Disease(MRD) in Childhood Acute Lymphoblastic Leukemia(ALL) in Relapse. A Children’s Oncology Group (COG) Study. (2004) (2)
- Pathology Residency Program Special Expertise Tracks Meet the Needs of an Evolving Field (2021) (2)
- Microwave Acceleration of the Metallization and Intensification of Cytochemical and Immunocytochemical Reaction Products with Silver Methenamine (1985) (2)
- Responding to HIV/AIDS in the East Asia and Pacific Region : A Strategy Note for the World Bank (2003) (2)
- PDE4B Modulates Glucocorticoid Sensitivity in Childhood Acute Lymphoblastic Leukemia (2012) (2)
- International Laboratory Comparison of Methodologies for Determining Minimal Residual Disease (MRD) in Childhood Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) (2015) (2)
- Cytotoxic T-cell allotaxis in human kidney rejection. (1983) (2)
- The Effects of a Systemwide Diagnostic Stewardship Change on West Nile Virus Disease Ordering Practices (2019) (2)
- Outcomes of Patients with Down Syndrome and CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG) (2020) (2)
- chapter ten Purchasing for quality of care (2006) (2)
- BLASTIC NATURAL KILLER CELL. AUTHORS' REPLY (1999) (2)
- Prognostic impact of minimal residual disease at the end of consolidation in NCI standard‐risk B‐lymphoblastic leukemia: A report from the Children's Oncology Group (2021) (2)
- Blastoid natural killer cell leukemia. (1999) (2)
- Guest Reviewer (2000) (2)
- A Randomized Trial of Sirolimus-Based Graft Versus Host Disease (GVHD) Prophylaxis After Hematopoietic Stem Cell Transplantation (HSCT) in Selected Patients with CR1 and CR2 ALL: Results From Children's Oncology Group Study ASCT0431 (2011) (2)
- Amplification of AML1 Does Not Impact Early Outcome of Children with Acute Lymphoblastic Leukemia (ALL) Treated with Risk-Directed Chemotherapy: A Report From the Children's Oncology Group (COG). (2009) (2)
- Pharmacogenetics of Minimal Residual Disease Response in Children with Acute Lymphoblastic Leukemia (ALL). (2004) (2)
- Factors considered in the 2008 WHO classification of myeloid neoplasms and acute leukemias (2010) (2)
- Experience with MRD Testing in B- ALL By Flow Cytometry Does Not Prevent Interpretative Discordance (2016) (2)
- Minimal Residual Disease Assessment of Remission after Induction Therapy Is Superior to Morphologic Assessment for Risk Stratification in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group (COG) (2016) (2)
- BPX-501 T cells interfere with minimal residual disease evaluation of B-cell acute lymphoblastic leukemia (2018) (2)
- Flow cytometry defended. (2000) (2)
- Minimal residual disease at end of induction and consolidation remain important prognostic indicators for newly diagnosed children and young adults with very high-risk (VHR) B-lymphoblastic leukemia (B-ALL): Children’s Oncology Group AALL1131. (2021) (2)
- Relationship of CRLF2 expression and outcome in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): A report from the Children's Oncology Group. (2011) (2)
- Clinical Characteristics and Treatment Outcome of Childhood Acute Lymphoblastic Leukemia With the t ( 4 ; l l ) ( q 21 ; q 23 ) : A Collaborative Study of 40 Cases (2003) (2)
- Lymphadenopathy, cough, and fever in a 51-year-old woman with systemic lupus erythematosus: case report of lymphomatoid granulomatosis. (2005) (2)
- High-Dose Cyclophosphamide (Cy), Rituximab, and a Cancer Vaccine for Relapsed Classical Hodgkin's Lymphoma (cHL) (2010) (2)
- Minimal Toxicity of Imatinib Mesylate in Combination with Intensive Chemotherapy for Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) in Children: A Report of the Children’s Oncology Group (COG) AALL0031 Protocol for Very High Risk ALL. (2006) (1)
- Philadelphia Chromosome Negative (Ph-) Very High Risk (VHR) Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents: The Impact of Intensified Chemotherapy on Early Event Free Survival (EFS) in Children’s Oncology Group (COG) Study AALL0031. (2008) (1)
- A Rise in CNS Lymphoproliferative Disease Incidence Reveals a Protective Role of Calcineurin Inhibitors (2014) (1)
- Outcomes of Children with Hematologic Malignancies Who Relapse After Allogeneic Hematopoietic Cell Transplantation (2012) (1)
- myeloid leukemia cells in acute - CD38 + A clinically relevant population of leukemic CD34 (2014) (1)
- Late-Relapse Diffuse Large B-Cell Lymphoma Frequently Represents Recurrence of the Original Disease, and Demonstrates Evidence of Superimposed Clonal Heterogeneity and Clonal Evolution (2014) (1)
- Temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukemia (ALL): A Children’s Oncology Group study. (2015) (1)
- Abstract 222: Genome-wide association study of acute lymphoblastic leukemia in children with Down syndrome (2018) (1)
- Children ' s Cancer Group lymphoblastic leukemia : a combined analysis of prognostic markers Risk-and response-based classification of childhood B-precursor acute (2007) (1)
- Minimal Residual Disease Testing in Acute Lymphoblastic Leukemia/Lymphoma (2018) (1)
- pediatric B-precursor acute lymphoblastic leukemia residual disease improve risk classification and outcome prediction in Gene expression classifiers for relapse-free survival and minimal (2010) (1)
- Absolute Lymphocyte Counts Refine MRD-Based Risk Stratification in Pediatric ALL. (2009) (1)
- Lymphadenopathy as the primary manifestation of malignant transformation in two patients with severe congenital neutropenia (2008) (1)
- Resolution of ambiguous low‐level positive quantitative polymerase chain reaction results in TEL‐AML1 positive ALL using a post‐PCR fluorescent oligoligation method * (2006) (1)
- Unusual locations for lymphomas. Case 3. Successive occurrence of peripheral T-cell lymphoma with bilateral conjuctival involvement in a patient with low-grade B-cell lymphoma. (2001) (1)
- A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-CRLF2-Rearranged JAK Pathway Alterations (2022) (1)
- Sex-Based Disparities in Outcome in Childhood Acute Lymphoblastic Leukemia (ALL): A Children's Oncology Group (COG) Report (2020) (1)
- Knock-in of a FLT3 Internal Tandem Duplication Mutation Cooperates with a NUP98-HOXD13 Fusion to Generate Acute Myeloid Leukemia (2011) (1)
- Bone Marrow Findings in Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide. (2019) (1)
- Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia (2018) (1)
- Genetically Defined Racial Differences Underlie Risk of Relapse in Childhood Acute Lymphoblastic Leukemia (2008) (1)
- Phase II results of mitoxantrone in combination with clofarabine in children with relapsed/refractory acute leukemia. (2019) (1)
- Syphilitic lymphadenitis with abscess formation involving cervical lymph nodes. (2018) (1)
- Terminal Differentiation of FLT3/ITD AML Blasts In Patients Treated with the FLT3 Inhibitor AC220 (2010) (1)
- The Response of FLT3/ITD AML to FLT3 Inhibition: Apoptosis of Peripheral Blood Blasts and Differentiation of Bone Marrow Blasts (2011) (1)
- Reply to ‘Quantification of marrow CD34+ cells: an important tool for distinguishing between hypoplastic myelodysplastic syndromes and aplastic anemia’ by A Orazi (2006) (1)
- Blastic Natural Killer Cell (1999) (1)
- Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631 (2021) (1)
- A Phase I Study of the Anti-Breast Cancer Immunotoxin 260F9 Mab-rRA Given by Intravenous Continuous Infusion (1989) (1)
- Blastic natural killer cell [1] (multiple letters) (1999) (0)
- Educational Case (2018) (0)
- lymphoma and leukemia Immunoglobulin and T cell receptor gene rearrangements in human (2011) (0)
- Correlation between Hematopoietic Stem Cell Engraftment Assay Results and Bone Marrow Biopsy, Flow Cytometry, and Cytogenetics Findings. (2004) (0)
- 1787. The Effects of a Systemwide Diagnostic Stewardship Change on West Nile Virus Disease Ordering Practices (2019) (0)
- Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children's Oncology Group Report (2021) (0)
- Oncology Group Study disease in pediatric acute lymphoblastic leukemia: a Children's , and minimal residual (2012) (0)
- Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932. (2023) (0)
- Outcome in Adolescent and Young Adult (AYA) Patients Compared to Younger Patients Treated for High-Risk B-Lymphoblastic Leukemia (HR B-ALL): Report from the Children's Oncology Group Study AALL0232 (2019) (0)
- Efficacy of a Brief, Cyclophosphamide-Intensive Regimen for Older Patients with Newly Diagnosed Burkitt's or Atypical Burkitt's Lymphoma/Leukemia. (2009) (0)
- Health Affairs reform : lessons from Europe The pharmaceutical industry and health (2001) (0)
- 2018 ASPHO ABSTRACTS (2018) (0)
- Supply chain disruptions due to the SARS‐CoV‐2 pandemic lead to an unusual preanalytical error in measuring hemoglobin concentration in a large medical center (2022) (0)
- Minimal Residual Disease in Acute Lymphoblastic Leukemia (2011) (0)
- Monitoring of MRD before and after Allogeneic Hematopoietic Cell Transplantation (HCT) of Childhood ALL by FC and RQ-PCR: A Retrospective Assessment on Behalf of the Pdwp of the Ebmt, the Cog, the Pbmtc, the I-Bfm and the Westhafen-Intercontinental-Group (2017) (0)
- Lymphoproliferative Disease Risk in Patients with Autoimmune Disease: Clustering of Primary CNS Lymphoma with Drug Regimen and Disease Process (2015) (0)
- Outcomes of Children with Hematologic Malignancies Who Relapse After Allogeneic Hematopoietic Cell Transplantation (AlloHCT) (2013) (0)
- 904 E-Rosette Positive (ER+), T Antigen Positive (T cell) Acute Lymphocytic Leukemia (ALL)-Patterns of Relapse (1985) (0)
- The International Consensus Classification of Acute Leukemias of Ambiguous Lineage. (2023) (0)
- Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia. (2023) (0)
- The genetic basis and cell of origin of mixed phenotype acute leukaemia (2018) (0)
- Inherited GATA3 genetic Variants Are Associated With Childhood BCR-ABL1-Like Acute Lymphoblastic Leukemia and Increased Risk Of Relapse (2013) (0)
- Heterogeneity of Minimal/Measurable Residual Disease (MRD) Practices in Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in the United States (2021) (0)
- 7th annual San Antonio flow cytometry forum (2004) (0)
- Molecular Classifiers for Prediction of Minimal Residual Disease (MRD) and Event Free Survival (EFS) Improve Risk Assignment at Diagnosis in Pediatric High-Risk B Precursor Acute Lymphoblastic Leukemia (ALL): A Children’s Oncology Group Study. (2007) (0)
- Abstract PR-2: Characterization of germline genetic variants underlying racial disparities of childhood leukemia outcome (2009) (0)
- 2018-10-27 LSU Opera - Eugene Onegin (2018) (0)
- 2018-11-20 LSU Bel Canto II (2018) (0)
- Blastoid natural killer cell leukemia [3] (multiple letters) (1999) (0)
- A novel ribonucleoprotein complex defined by monoclonal antibodies to NIH 3T3 cells transfected with human pancreatic adenocarcinoma DNA. (1990) (0)
- Factors Predictive of Relapse of Hematologic Malignancies in Pediatric Patients Post Allogeneic Hematopoietic Cell Transplantation (2012) (0)
- Comparison of High-Throughput Sequencing and Flow Cytometry for Measuring Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia: A Children's Oncology Group Cohort (2012) (0)
- childhood T-cell acute lymphoblastic leukemia in immunodeficient mice Preconditioning with fetal cord blood facilitates engraftment of primary (2013) (0)
- Strategic issues in health care management: Edited by M. Malek, J. Rasquinha, P. Vacani 279 pp., John Wiley (1994) (0)
- A clinically relevant population of leukemic CD34 (cid:1) CD38 (cid:2) cells in acute myeloid leukemia (2012) (0)
- Epstein-Barr Virus–Associated Central Nervous System Lymphoproliferative Disease in a Patient with Acquired Immunodeficienc Syndrome Responsive to Highly Active Antiretroviral Therapy (2008) (0)
- BLASTOID NATURAL KILLER CELL LEUKEMIA. AUTHORS' REPLY (1999) (0)
- CNS Disease at Diagnosis May Predict Relapse of Hematologic Malignancies in Pediatric Patients After Allogeneic Hematopoietic Cell Transplantation (AlloHCT) (2013) (0)
- Prognostic Significance of Immunophenotyping in Acute Lymphoblastic Leukemia (1990) (0)
- PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia (2019) (0)
- Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia (2012) (0)
- Infectious Disease Pathology (2017) (0)
- Final Results of Phase I/II Trial of Mitoxantrone in Combination with Clofarabine (MITCL) in Children with Relapsed/Refractory Acute Leukemia (2022) (0)
- Flow Cytometric Screening of Novel Antigen Expression in T- ALL (2012) (0)
- Epstein-Barr virus-associated central nervous system lymphoproliferative disease in a patient with acquired immunodeficiency syndrome responsive to highly active antiretroviral therapy. (2008) (0)
- Flow cytometric analysis of fine needle aspirates is affected by tumor subtype, but not by anatomic location nor technique (2020) (0)
- Comparison of Diagnostic and Relapse Flow Cytometry Phenotypes in Childhood ALL: Implications for Residual Disease (MRD) Detection. (2004) (0)
- Oncology Group study Monoclonal antibody definition of T cell acute leukemia: a Pediatric (2011) (0)
- Early Response Characteristics and Blast Cytogenetic FEatures In 5,377 Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): A Children's Oncology Group (COG) Study (2010) (0)
- 15 – Flow Cytometry in Oncologic Diagnosis (2013) (0)
- Early Response to Therapy Is Significantly Associated with Genetic Subtype of Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group. (2007) (0)
- Childhood A cute L ymphoblastic L eukemia W ith t he MLL-ENL Fusion a nd t (11;19)(q23;p13 .3) T ranslocation (1999) (0)
- 2018-11-19 LSU Bel Canto I (2018) (0)
- A Health Systems Approach to TB Infection Control in Central Asia (2009) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Michael J. Borowitz?
Michael J. Borowitz is affiliated with the following schools:
